Clinical pharmacology of nervous system diseases.

The research paper primarily discusses the limitations and potential improvements in drug-based treatment for neurological diseases in horses. It emphasizes the need for more research into the pharmacokinetics and pharmacodynamics of these drugs, as well as the ethical considerations around using behavioral pharmacology.

Therapeutic Options and Limitations in Treating Neurological Diseases

• This research paper focuses on investigating the pharmacological treatment of neurological diseases in horses, which is often complicated by the well-developed defense barriers of the Central Nervous System (CNS) and the high cost of drug therapy.
• These defense barriers, which include the presence of protective barriers such as the blood-brain barrier, can limit the availability of drugs to the CNS, making effective treatment of neurologic diseases in horses more challenging.

Improvements in Treatment of Bacterial Meningitis

• The paper discusses how recent discoveries in controlling inflammation in the horse’s CNS can enhance treatment outcomes for bacterial meningitis, a critical neurological disease.
• This improvement could potentially reduce the severity of symptoms and expedite recovery in affected horses.

Controversy Surrounding EPM Treatment

• The paper mentions that the correct pharmacological treatment for Equine Protozoal Myeloencephalitis (EPM) continues to be disputed within the scientific community.
• The authors suggest that this debate necessitates additional study for reaching a consensus on the most effective treatment.

The Need for Additional Research

• The researchers highlight a critical need for studying the pharmacokinetics and pharmacodynamics of CNS drugs, which deal with the body’s effect on the drug and the drug’s action on the body, respectively. This information could lead to more efficient dosage and drug administration strategies, thus improving treatment efficacy.

Ethics of Behavioral Pharmacology in Performance Horses

• The paper notes that while behavioral pharmacology has become popular in human and small animal medicine, its use in performance horses needs careful evaluation due to potential ethical implications.
• The researchers emphasize the careful consideration of whether the use of behavioral pharmacology in performance horses could lead to their exploitation or harm, particularly in competitive environments.